Companies: 10,795·Total market cap: $144.5T
Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc.

AMLXNASDAQHealthcare● Active
$13.01
$-0.31(-2.33%)
Market Cap$1.1B
P/E Ratio
52W High$18.605
52W Low$4.76
Overview

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

amlx · stock forecast · 11 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 11 Wall Street analysts in the past 3 months

SellBuy

Buy

11 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
10
Hold
1
Sell
0
Strong Sell
0
Total: 11 · Buy rate: 90.9%

12-Month Price Target

High

$34.00

Consensus

$27.50

+112.3% upside

Low

$21.00

Median: $27.5 · Last Close: $12.96

The Amylyx Pharmaceuticals, Inc. (AMLX) analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month AMLX price target is $27.50, representing +112.3% upside from the current price of $12.96.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $28 (112.3%)

Consensus Target

$27.50

112.3% upside

High Target

$34

162.4%

Low Target

$21

62.1%

Current Price

$12.96

as of today

Based on analyst price targets, the AMLX stock price prediction for the next 12 months ranges from $21 to $34. The consensus AMLX price forecast of $27.50 implies 112.3% upside from the current price of $12.96.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$12.731.78%

1-day model range: $12.64–$12.81. Peak: $12.81 (-1.78%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$22+68.5%
2028$30+131.9%
2029$36+179.9%
2030$40+211.8%
2031+231.3%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

0%7%93%
0Buy
1Neutral
13Sell
RSI (14)50.8Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · AMLX · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$13.42SELL
MA 10$13.75SELL
MA 20$13.76SELL
MA 50$15.22SELL
MA 100$14.83SELL
MA 200$13.84SELL
Current $AMLX · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$13.43SELL
EMA 10$13.62SELL
EMA 20$14.00SELL
EMA 50$14.57SELL
EMA 100$14.41SELL
EMA 200$13.08SELL
Current $AMLX · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Mizuho2026-04-28
Maintains
OutperformOutperform
HC Wainwright & Co.2026-03-25
Maintains
BuyBuy
Guggenheim2026-03-19
Maintains
BuyBuy
HC Wainwright & Co.2026-03-04
Maintains
BuyBuy
B of A Securities2026-02-20
Maintains
BuyBuy
HC Wainwright & Co.2026-02-10
Maintains
BuyBuy
HC Wainwright & Co.2025-11-07
Maintains
BuyBuy
Citigroup2025-10-17
Maintains
BuyBuy
Baird2025-10-16
Maintains
OutperformOutperform
B of A Securities2025-10-03
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Amylyx Pharmaceuticals, Inc. (AMLX) stock. Of the recent 64 rating actions, 4 were upgrades and 5 were downgrades. 11 analysts currently cover AMLX.

Analyst Recommendation Trends

Buy ratings211
Hold ratings00
Sell ratings00

AMLX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$0M

↓ 99.9% YoY

Revenue Next Year

$45M

↑ 55323.5% YoY

EPS This Year

$-1.41

EPS Next Year

$-1.27

↓ 9.9% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast AMLX EPS of $-1.41 for the current fiscal year, based on estimates from 7 analysts. The AMLX revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The AMLX stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AMLX price target is $27.50 (+112.3% upside), with an analyst consensus of Buy.

The AMLX short-term stock prediction for tomorrow is $12.73 (-1.78%). The AMLX stock price prediction for 2027 estimates an average of $22. The AMLX stock prediction for 2030 projects a range of $37–$43.

Amylyx Pharmaceuticals, Inc. trades on NASDAQ under the ticker AMLX. The AMLX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 91% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

AMLX forecast · 8 questions

According to 11 Wall Street analysts, the average 12-month AMLX price target is $27.50, with a high forecast of $34.00 and a low of $21.00. The median price target is shown in the chart above when available. This implies +112.3% potential upside from the current price of $12.96.

AMLX price targetWhat is AMLX price targetAMLX analyst price targetAMLX 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.